Bayer and Evotec have recently signed a five-year, multi-target research pact with the aim to develop multiple clinical candidates for the treatment of chronic kidney diseases.
Both parties will contribute novel drug targets and a comprehensive set of high-quality technology platforms to jointly develop new innovative treatment options for patients, and will share responsibilities during preclinical development. Continue reading
A study funded by the NIHR, NIH, Wellcome Trust and the Medical Research Council have discovered 31 new gene regions that are linked with blood pressure. Hailed as one of the largest studies to date, the study involves over 347,000 people led by Queen Mary’s university of London and the University of Cambridge.
Our Brexit industry analytics report was created as a product of the Clinical Professionals Group collaboration with VacancySoft. The ongoing partnership aims to produce a regular report that provides an extensive analysis of the vacancies available in a variety of different sectors, countries and areas of the life sciences industry. Continue reading
We are delighted to announce that The Clinical Professionals group are shortlisted for the APSCo “Recruitment Company with the Most Sustainable Growth” award.
The award recognises companies that have shown consistent growth over the past 5 years whilst demonstrating the professional values and exceptional performance associated with APSCo membership. We were required to demonstrate how this growth was achieved, what set us apart from others, how we develop and train staff whilst also ensuring our company is legally and ethically compliant. Continue reading
Throughout August, The Clinical Professionals Group celebrated the Olympics with our very own Rio themed activities to help raise money for our corporate charity, the Arrows Group Foundation.
Whilst not only taking part in a results driven competition each week, Clinical Professionals employees also celebrated every Friday with fancy dress, bake sales and fun activities. Continue reading
As many students begin to embark upon their journey through university next month, many who have already graduated and obtained their degree can be at a loss for what to do next, but we have the solution…
Quite often graduates find themselves looking to begin their career within their particular specialisation, but are often turned down due to lack of experience or gaps within their training and the Life Science industry is no different. Continue reading
After a period of speculation Pfizer has recently stepped forward with a $14-billion bid for Medivation, trouncing Sanofi and other suitors in a move designed to boost its oncology portfolio.
Pfizer announced a definitive merger agreement under which it will acquire the US biopharma (which is currently focused on developing and commercialising small molecules for oncology) for $81.50 a share in cash, to be financed with existing funds. Continue reading
Pfizer Inc. announced the recent publication of a post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid polyneuropathy (TTR-FAP). The analysis, which included patients with the Val30Met mutation treated over varying periods of up to 5 and a half years, showed that treatment with VYNDAQEL initiated during the early stage of the disease resulted in minimal neurological disease progression and in preservation of body weight, which often declines as the disease progresses. VYNDAQEL was well tolerated with no new safety signals observed. Continue reading
Last month our CEO, Yvette Cleland, contributed her thoughts and opinions on the staff shortage crisis currently affecting the clinical research industry to a BioPharm Insight article:
The CRO industry’s acute understaffing issue is likely to become more of a burden to sponsors and CROs as trial volumes increase while recruitment stagnates, said experts. While the issue — not enough qualified, experienced clinical research staff globally — has no clear immediate fix, several industry schemes may partly alleviate specific training gaps in the long- term, they said.
On Thursday June 23rd 2016, the UK voted in tens of millions on whether the UK should remain within the European Union. The following day it was announced that the UK will be set to leave the EU with the votes swaying 51.9% for leave and 48.1% for remain, with a 72.2% turnout.
In light of the result and after reflection around this new uncertainty for UK Life Sciences Clinical Professional’s CEO Yvette Cleland has released the following statement on the matter: Continue reading